492 related articles for article (PubMed ID: 34953513)
41. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.
Collier DA; De Marco A; Ferreira IATM; Meng B; Datir RP; Walls AC; Kemp SA; Bassi J; Pinto D; Silacci-Fregni C; Bianchi S; Tortorici MA; Bowen J; Culap K; Jaconi S; Cameroni E; Snell G; Pizzuto MS; Pellanda AF; Garzoni C; Riva A; ; Elmer A; Kingston N; Graves B; McCoy LE; Smith KGC; Bradley JR; Temperton N; Ceron-Gutierrez L; Barcenas-Morales G; ; Harvey W; Virgin HW; Lanzavecchia A; Piccoli L; Doffinger R; Wills M; Veesler D; Corti D; Gupta RK
Nature; 2021 May; 593(7857):136-141. PubMed ID: 33706364
[TBL] [Abstract][Full Text] [Related]
42. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.
Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA
EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493
[TBL] [Abstract][Full Text] [Related]
43. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
[TBL] [Abstract][Full Text] [Related]
44. B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19.
Zollner A; Watschinger C; Rössler A; Farcet MR; Penner A; Böhm V; Kiechl SJ; Stampfel G; Hintenberger R; Tilg H; Koch R; Antlanger M; Kreil TR; Kimpel J; Moschen AR
EBioMedicine; 2021 Aug; 70():103539. PubMed ID: 34391087
[TBL] [Abstract][Full Text] [Related]
45. T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study.
Angyal A; Longet S; Moore SC; Payne RP; Harding A; Tipton T; Rongkard P; Ali M; Hering LM; Meardon N; Austin J; Brown R; Skelly D; Gillson N; Dobson SL; Cross A; Sandhar G; Kilby JA; Tyerman JK; Nicols AR; Spegarova JS; Mehta H; Hornsby H; Whitham R; Conlon CP; Jeffery K; Goulder P; Frater J; Dold C; Pace M; Ogbe A; Brown H; Ansari MA; Adland E; Brown A; Chand M; Shields A; Matthews PC; Hopkins S; Hall V; James W; Rowland-Jones SL; Klenerman P; Dunachie S; Richter A; Duncan CJA; Barnes E; Carroll M; Turtle L; de Silva TI;
Lancet Microbe; 2022 Jan; 3(1):e21-e31. PubMed ID: 34778853
[TBL] [Abstract][Full Text] [Related]
46. A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses.
Tauzin A; Gong SY; Chatterjee D; Ding S; Painter MM; Goel RR; Beaudoin-Bussières G; Marchitto L; Boutin M; Laumaea A; Okeny J; Gendron-Lepage G; Bourassa C; Medjahed H; Goyette G; Williams JC; Bo Y; Gokool L; Morrisseau C; Arlotto P; Bazin R; Fafard J; Tremblay C; Kaufmann DE; De Serres G; Richard J; Côté M; Duerr R; Martel-Laferrière V; Greenplate AR; Wherry EJ; Finzi A
Cell Rep; 2022 Oct; 41(4):111554. PubMed ID: 36244343
[TBL] [Abstract][Full Text] [Related]
47. The Impact of Time between Booster Doses on Humoral Immune Response in Solid Organ Transplant Recipients Vaccinated with BNT162b2 Vaccines.
Hamm SR; Loft JA; Pérez-Alós L; Heftdal LD; Hansen CB; Møller DL; Pries-Heje MM; Hasselbalch RB; Fogh K; Hald A; Ostrowski SR; Frikke-Schmidt R; Sørensen E; Hilsted L; Bundgaard H; Garred P; Iversen K; Perch M; Sørensen SS; Rasmussen A; Sabin CA; Nielsen SD
Viruses; 2024 May; 16(6):. PubMed ID: 38932153
[TBL] [Abstract][Full Text] [Related]
48. Assessment of humoral and cellular immunity induced by the BNT162b2 SARS-CoV-2 vaccine in healthcare workers, elderly people, and immunosuppressed patients with autoimmune disease.
Malipiero G; Moratto A; Infantino M; D'Agaro P; Piscianz E; Manfredi M; Grossi V; Benvenuti E; Bulgaresi M; Benucci M; Villalta D
Immunol Res; 2021 Dec; 69(6):576-583. PubMed ID: 34417958
[TBL] [Abstract][Full Text] [Related]
49. Altered transcriptomic immune responses of maintenance hemodialysis patients to the COVID-19 mRNA vaccine.
Chang YS; Huang K; Lee JM; Vagts CL; Ascoli C; Amin MR; Ghassemi M; Lora CM; Edafetanure-Ibeh R; Huang Y; Cherian RA; Sarup N; Warpecha SR; Hwang S; Goel R; Turturice BA; Schott C; Hernandez M; Chen Y; Jorgensen J; Wang W; Rasic M; Novak RM; Finn PW; Perkins DL
Elife; 2024 Apr; 13():. PubMed ID: 38656290
[TBL] [Abstract][Full Text] [Related]
50. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.
Garcia-Beltran WF; Lam EC; St Denis K; Nitido AD; Garcia ZH; Hauser BM; Feldman J; Pavlovic MN; Gregory DJ; Poznansky MC; Sigal A; Schmidt AG; Iafrate AJ; Naranbhai V; Balazs AB
Cell; 2021 Apr; 184(9):2372-2383.e9. PubMed ID: 33743213
[TBL] [Abstract][Full Text] [Related]
51. mRNA vaccination drives differential mucosal neutralizing antibody profiles in naïve and SARS-CoV-2 previously-infected individuals.
Longet S; Hargreaves A; Healy S; Brown R; Hornsby HR; Meardon N; Tipton T; Barnes E; Dunachie S; Duncan CJA; Klenerman P; Richter A; Turtle L; de Silva TI; Carroll MW
Front Immunol; 2022; 13():953949. PubMed ID: 36159846
[TBL] [Abstract][Full Text] [Related]
52. Antibody affinity maturation and cross-variant activity following SARS-CoV-2 mRNA vaccination: Impact of prior exposure and sex.
Tang J; Grubbs G; Lee Y; Huang C; Ravichandran S; Forgacs D; Golding H; Ross TM; Khurana S
EBioMedicine; 2021 Dec; 74():103748. PubMed ID: 34902788
[TBL] [Abstract][Full Text] [Related]
53. Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination.
Goel RR; Apostolidis SA; Painter MM; Mathew D; Pattekar A; Kuthuru O; Gouma S; Hicks P; Meng W; Rosenfeld AM; Dysinger S; Lundgreen KA; Kuri-Cervantes L; Adamski S; Hicks A; Korte S; Oldridge DA; Baxter AE; Giles JR; Weirick ME; McAllister CM; Dougherty J; Long S; D'Andrea K; Hamilton JT; Betts MR; Luning Prak ET; Bates P; Hensley SE; Greenplate AR; Wherry EJ
Sci Immunol; 2021 Apr; 6(58):. PubMed ID: 33858945
[TBL] [Abstract][Full Text] [Related]
54. Heterologous immunization with BNT162b2 followed by mRNA-1273 in dialysis patients: seroconversion and presence of neutralizing antibodies.
Kohmer N; Rabenau HF; Ciesek S; Krämer BK; Göttmann U; Keller C; Rose D; Blume C; Thomas M; Lammert A; Lammert A
Nephrol Dial Transplant; 2022 May; 37(6):1132-1139. PubMed ID: 35099023
[TBL] [Abstract][Full Text] [Related]
55. Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses.
Almendro-Vázquez P; Chivite-Lacaba M; Utrero-Rico A; González-Cuadrado C; Laguna-Goya R; Moreno-Batanero M; Sánchez-Paz L; Luczkowiak J; Labiod N; Folgueira MD; Delgado R; Paz-Artal E
Front Immunol; 2022; 13():981350. PubMed ID: 36059485
[TBL] [Abstract][Full Text] [Related]
56. BNT162b vaccines protect rhesus macaques from SARS-CoV-2.
Vogel AB; Kanevsky I; Che Y; Swanson KA; Muik A; Vormehr M; Kranz LM; Walzer KC; Hein S; Güler A; Loschko J; Maddur MS; Ota-Setlik A; Tompkins K; Cole J; Lui BG; Ziegenhals T; Plaschke A; Eisel D; Dany SC; Fesser S; Erbar S; Bates F; Schneider D; Jesionek B; Sänger B; Wallisch AK; Feuchter Y; Junginger H; Krumm SA; Heinen AP; Adams-Quack P; Schlereth J; Schille S; Kröner C; de la Caridad Güimil Garcia R; Hiller T; Fischer L; Sellers RS; Choudhary S; Gonzalez O; Vascotto F; Gutman MR; Fontenot JA; Hall-Ursone S; Brasky K; Griffor MC; Han S; Su AAH; Lees JA; Nedoma NL; Mashalidis EH; Sahasrabudhe PV; Tan CY; Pavliakova D; Singh G; Fontes-Garfias C; Pride M; Scully IL; Ciolino T; Obregon J; Gazi M; Carrion R; Alfson KJ; Kalina WV; Kaushal D; Shi PY; Klamp T; Rosenbaum C; Kuhn AN; Türeci Ö; Dormitzer PR; Jansen KU; Sahin U
Nature; 2021 Apr; 592(7853):283-289. PubMed ID: 33524990
[TBL] [Abstract][Full Text] [Related]
57. Rapid induction of antigen-specific CD4
Painter MM; Mathew D; Goel RR; Apostolidis SA; Pattekar A; Kuthuru O; Baxter AE; Herati RS; Oldridge DA; Gouma S; Hicks P; Dysinger S; Lundgreen KA; Kuri-Cervantes L; Adamski S; Hicks A; Korte S; Giles JR; Weirick ME; McAllister CM; Dougherty J; Long S; D'Andrea K; Hamilton JT; Betts MR; Bates P; Hensley SE; Grifoni A; Weiskopf D; Sette A; Greenplate AR; Wherry EJ
Immunity; 2021 Sep; 54(9):2133-2142.e3. PubMed ID: 34453880
[TBL] [Abstract][Full Text] [Related]
58. Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2).
Favresse J; Bayart JL; Mullier F; Dogné JM; Closset M; Douxfils J
Clin Microbiol Infect; 2021 Sep; 27(9):1351.e5-1351.e7. PubMed ID: 33975007
[TBL] [Abstract][Full Text] [Related]
59. Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine.
Gebre MS; Rauch S; Roth N; Yu J; Chandrashekar A; Mercado NB; He X; Liu J; McMahan K; Martinot A; Martinez DR; Giffin V; Hope D; Patel S; Sellers D; Sanborn O; Barrett J; Liu X; Cole AC; Pessaint L; Valentin D; Flinchbaugh Z; Yalley-Ogunro J; Muench J; Brown R; Cook A; Teow E; Andersen H; Lewis MG; Boon ACM; Baric RS; Mueller SO; Petsch B; Barouch DH
Nature; 2022 Jan; 601(7893):410-414. PubMed ID: 34794169
[TBL] [Abstract][Full Text] [Related]
60. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects.
Pham MN; Murugesan K; Banaei N; Pinsky BA; Tang M; Hoyte E; Lewis DB; Gernez Y
J Allergy Clin Immunol; 2022 Mar; 149(3):907-911.e3. PubMed ID: 34952033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
